Targeting Telomerase As Therapeutic Strategy for Melanoma

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

Researchers target telomerase for killing NRAS-mutant melanoma cells

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

Once Monthly Opdivo Use Approved in EU for Certain Melanoma, Renal Cell Cancer Patients

The European Commission has approved a new dosing schedule for Opdivo(nivolumab), allowing the PD-1 inhibitor to be given every four weeks to patients with advanced melanoma and those with previously treated renal cell carcinoma.

BGB324 (bemcentinib)

BGB324 (bemcentinib), from BerGenBio, is being developed as a treatment for triple-negative breast cancer, non-small cell lung cancer (NSCLC), acute myeloid leukemia, myelodysplastic syndrome, and metastatic melanoma.

Cancer in the News

Feature Articles

Banning Many Sunscreen Products Will Increase Skin Cancer Risk

Today, more than 70 percent of all sunscreens contain the critical ingredients oxybenzone or octinoxate for a good reason: they provide the vital broad-spectrum protection for high SPF sunscreens to block both UVA and UVB ultraviolet rays that can cause skin aging, skin damage and skin cancer.

Read the full story

Posted in Melanoma In The News, Patient Information

4 Ways to Protect Against Skin Cancer (Other Than Sunscreen)

It’s almost May and here in the Northeast, front-of-the-pharmacy aisles are filled with myriad brands and types of sunscreen.

Read the full story

Posted in Melanoma In The News, Patient Information

FDA approves Tafinlar-Mekinist combination for adjuvant treatment of BRAF-mutant melanoma

The FDA approved the combination of dabrafenib and trametinib for adjuvant treatment of patients with BRAF V600E- or BRAF V600K-positive melanoma that has spread to their lymph nodes.

Read the full story

Posted in Melanoma In The News, FDA

Million-dollar boost for dermatology research

Early detection of melanoma research has received a $1.195 million Partnership Grant from the National Health and Medical Research Council (NHMRC).

Read the full story

Posted in Melanoma In The News, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories